Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (NASDAQ: GANX) is a clinical-stage biotech company pioneering novel small molecule therapies for neurodegenerative diseases and rare genetic disorders through its proprietary computational drug discovery platform. This page serves as the definitive source for verified updates on clinical trials, research breakthroughs, and corporate developments.
Investors and researchers will find timely updates on the company’s lead candidate GT-02287 for Parkinson’s disease, along with pipeline progress across lysosomal storage disorders and oncology targets. Our curated news collection includes earnings reports, partnership announcements, and scientific presentations – all essential for understanding GANX’s position in the competitive biopharmaceutical landscape.
Key updates cover three critical areas: clinical trial milestones for brain-penetrant therapies, advancements in AI-driven target identification via the Magellan platform, and strategic collaborations accelerating therapeutic development. Bookmark this page to track how GANX’s focus on allosteric modulation could reshape treatment paradigms.
Gain Therapeutics announced the pricing of an $11.0 million public offering, consisting of 7,116,547 common shares at $1.35 per share and pre-funded warrants for 1,031,602 shares. The pre-funded warrants are exercisable immediately. Gain has also given the underwriter a 30-day option to purchase an additional 1,222,222 common shares. Titan Partners Group is the sole bookrunner. The offering is set to close around June 17, 2024, pending customary conditions. The proceeds will support clinical and nonclinical development of GT-02287 for neurodegenerative diseases and other corporate purposes. The securities are being offered via a prospectus supplement, which is available on the SEC's website.
Gain Therapeutics, a Nasdaq-listed company (GANX), announced a public offering of its common stock and pre-funded warrants. The offering's final terms will depend on market conditions. Gain plans to use the proceeds to further develop its lead candidate, GT-02287, aimed at treating neurodegenerative diseases like GBA1 Parkinson's disease, and for general corporate purposes. Titan Partners Group is the sole bookrunner for this offering. All securities will be offered by Gain under a previously filed shelf registration statement with the SEC.
Gain Therapeutics has announced that its late-breaking abstract on GT-02287, a clinical-stage GCase enhancer, has been accepted for presentation at the FENS Forum 2024 in Vienna. New data reveals improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The presentation is scheduled for June 27, 2024, and will be delivered by Dr. Beatriz Calvo-Flores Guzman. The FENS Forum is Europe's largest neuroscience congress, encompassing both basic and translational research. This recognition could potentially highlight the innovative strides Gain Therapeutics is making in the biotechnology sector, particularly in treating neurodegenerative diseases.
Gain Therapeutics (Nasdaq: GANX) has released its Q1 2024 financial results, reporting positive developments despite a decrease in both R&D and G&A expenses. The company announced favorable outcomes from the SAD part of its Phase 1 GT-02287 trial, initiated the MAD portion, and presented promising data on neuroprotection in Parkinson’s models.
Key executive appointments were made, with Gene Mack as CFO and Jonas Hannestad as CMO. The company maintains a cash runway into 2025, supported by potential grant applications. Financially, R&D expenses decreased by $0.3M to $2.5M, and G&A expenses fell by $0.6M to $1.9M. Net loss per share improved to $0.22 from $0.43 YoY. Cash reserves dropped to $12.7M from $16.8M year-end 2023.
